Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Action Johne’s Conference to hear about promising trials of Actiphage for milk testing

Date: 30 January 2019

Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne’s disease, a wasting condition of livestock - and is shed into the milk of infected animals. The presence of MAP can be detected in milk using Actiphage®, a new test that has the potential to provide a new paradigm in milk testing; as a quality assurance tool for dairy producers and in helping farmers to control this chronic disease.
dairy cow

Dr Ben Swift, Director of R&D at PBD Biotech, will be talking about this new, highly sensitive test at the Action Johne’s Conference later this month (30 January). Highlighting how Actiphage, applied to both blood and milk samples, can help dairy farmers and producers.

Currently the only test for viable MAP in milk is culturing the bacteria in the laboratory, which takes many weeks and is not very sensitive.

Dr Ben Swift comments, “Actiphage directly detects MAP using a type of virus, known as a bacteriophage, which only infects live mycobacteria and can penetrate their thick cell wall. Once inside the mycobacteria the phage grows rapidly and eventually breaks open the cell, releasing the bacterial DNA, which can then be sensitively detected, confirming of the presence or absence of MAP in milk or blood within hours.”

Dr Swift will explain that Actiphage offers higher sensitivity as a milk test. Currently the dairy industry conducts routine milk tests to detect and monitor antibodies against the bacteria, but the Actiphage technology shows that commercially available milk contains low levels of live bacteria even after pasteurisation. The presence of live MAP in retail milk is of increasing concern as the bacterium is under growing scrutiny for its possible role in Crohn’s disease.*

Commenting on one of the milk trials undertaken at the University of Nottingham, which was published in leading journal Food Microbiology, Dr Swift said, “In this controlled study, Actiphage was able to detect just 1-2 mycobacteria cells per 50 ml of pasteurised milk, highlighting just how sensitive this novel technology is.”

The Actiphage diagnostic provides an opportunity for the dairy industry to improve quality assurance at every stage of the value food chain as well as providing feedback on herd health and management of Johne’s disease.

“This new technology has the potential to revolutionise the control and understanding of mycobacterial infection and control from livestock, wildlife and human health and has strong potential for application in food quality control too,” said PBD Biotech’s Commercial Director Mark Hammond.

“Actiphage gives dairy producers, vets and farmers a head start on the race to discover live mycobacteria, and provides another tool in the management of food quality and animal welfare.”

Actiphage can also be used on blood samples to identify infection. Traditional tests for MAP rely on either detecting an antibody response to the infection using ELISA tests for blood or milk, or culture of the Mycobacterium organism.

The Action Johne’s Conference will take place on at the Sixways Stadium, Worcester on Wednesday 30 January 2019.

* References for the implication of MAP in the development of Crohn’s disease

Bull et al, 2003. Detection and verification of Mycobacterium avium subsp paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn’s disease. Journal of Clinical Microbiology, 41, 2915-2923

Feller et al, 2007. Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infectious Diseases. 7, 607-613

Rhodes et al, 2014. Mycobacterium avium Subspecies paratuberculosis: Human Exposure through Environmental and Domestic Aerosols. Pathogens. 3,557-595.

Share:
  • Events, Johne's Disease

Related posts

Loading...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to talk about our new blood test and bulk milk test with producers, cheesemakers, dairy companies and others across the industry...
See PBD Biotech at The Dairy Show

5 October 2022

See us at The Dairy Show

September 6, 2022
Ensuring consumer confidence in dairy products has never been more vital and we are delighted to have the opportunity to...
ICP 2022

12 -16th June 2022

ICP 2022

May 26, 2022
The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International Association for Paratuberculosis Colloquium (ICP2022) in Dublin on 12 – 16th June 2022.
ICP 2022

12 -16th June 2022

ICP 2022

May 26, 2022
The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International...
Cath Rees

21-23 August 2022

The Science of Artisan Cheese

May 25, 2022
Prof. Cath Rees CSO has spoken at the conference on several occasions and is delighted to be invited back to talk about developments in Actiphage, and its application to test milk for the presence of bTB and MAP.
Cath Rees

21-23 August 2022

The Science of Artisan Cheese

May 25, 2022
Prof. Cath Rees CSO has spoken at the conference on several occasions and is delighted to be invited back to...
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of mycobacteria in the blood is an indication that the animal is infected and has the potential to develop disease.
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of...
1 2 … 5 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More